Androgenic decline is the physiological process characterized by a gradual, age-associated reduction in the production and bioavailability of androgens, primarily testosterone and dehydroepiandrosterone (DHEA), in both males and females. This reduction often manifests clinically as diminished libido, decreased bone mineral density, and changes in body composition, including sarcopenia. It is a natural, yet variable, part of the aging endocrine landscape.
Origin
The term derives from the Greek andrós, meaning “of a man,” and gennán, meaning “to produce,” referring to male-producing hormones, combined with the Latin declinare, meaning “to bend down” or “sink.” Clinically, it is a key component of conditions like late-onset hypogonadism in men, though the phenomenon is recognized across sexes. Its study is central to endocrinology and men’s hormonal health.
Mechanism
The decline stems from alterations in the hypothalamic-pituitary-gonadal (HPG) axis, leading to reduced testicular or adrenal gland output. Furthermore, age-related increases in Sex Hormone-Binding Globulin (SHBG) reduce the fraction of bioavailable free testosterone, limiting hormone action at the target cell receptor level. This cascade of events impairs androgenic signaling necessary for maintaining muscle mass, energy, and cognitive function.
We use cookies to personalize content and marketing, and to analyze our traffic. This helps us maintain the quality of our free resources. manage your preferences below.
Detailed Cookie Preferences
This helps support our free resources through personalized marketing efforts and promotions.
Analytics cookies help us understand how visitors interact with our website, improving user experience and website performance.
Personalization cookies enable us to customize the content and features of our site based on your interactions, offering a more tailored experience.